Full Press Release Details
Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Market Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides" has been added to ResearchAndMarkets.com's offering.
This report represents an essential resource for stakeholders seeking to navigate and capitalize on the evolving landscape of cancer molecular diagnostics. The insights and market forecasts will empower decision-makers with the tools necessary to drive growth and innovation in their respective sectors. By understanding these emerging trends and technological advancements, stakeholders can position themselves at the forefront of industry transformation.
The cancer molecular diagnostics industry is witnessing a robust resurgence, marked by accelerating growth across various segments. An emerging segment, Cancer Companion Diagnostics, is transforming the landscape and driving sector expansion. Over 140 companies are profiled in this comprehensive analysis, as industry trends catalyze growth and boost company valuations. Key trends invigorating this market include personalized medicine, pharmacogenomics, liquid biopsy innovations, minimal residual disease testing, and the rise of new economies with expansive markets. Additionally, the shift from traditional physician diagnostics to intelligent diagnostic tests underscores a paradigm shift in the industry.
Companion diagnostics is particularly at the forefront of technological innovations. These advancements promise a dynamic and evolving global market where singular laboratories can extend their services to a vast global patient base. This adaptability signifies a turning point in how diagnostic services are provided and consumed worldwide.
The report offers invaluable data for analysts and planners. It includes hundreds of pages of insights, such as detailed United States Medicare Fee Payment Schedules to help stakeholders understand test pricing intricacies. This information is crucial for facilities planning decisions, demand forecasting for novel testing protocols, and directing research investments efficiently.
Providing specific growth and market size estimates for emerging technology tests is part of the package, with no additional charges. Existing laboratories and hospitals can leverage this granular data to forecast and strategize their clinical facilities' growth trajectories. The report ensures that users receive support in utilizing this information, enhancing the value proposition for purchasers.
The document offers detailed analytical breakouts for 18 countries and 4 regions, and upon purchasing, a detailed analysis for any country globally is readily available. This global breadth ensures comprehensive market insights tailored to varied geographical needs. Furthermore, a five-year market forecast is included, equipping stakeholders with forward-looking perspectives critical for strategic planning and investment.
1.1 Cancer MDx - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3.1.1 Traditional Market Segmentation
3.1.2 Laboratory Focus and Segmentation
3.2 Industry Structure
3.2.1 Hospital Testing Share
3.2.2 Economies of Scale
3.2.3 Physician Office Lab's
3.2.4 Physicians and POCT
4.1 Factors Driving Growth
4.1.1 New Diagnostics Create New Markets
4.1.2 New Roles for Diagnostics
4.1.4 Expanding the Pharmaceutical Toolbox
4.1.5 Regulatory Retreat
4.2 Factors Limiting Growth
4.2.1 Falling Prices
4.2.3 Wellness has a Downside
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
4.3.11 Multiplexing and Foundation One
4.3.12 Pharmacogenomics Technology
4.3.13 Gene Editing and Gene Therapy
5 Molecular Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.2 Foundation Medicine, Repare Therapeutics to Develop CDx
5.3 NHS Declines to Accelerate Grail Galleri Implementation
5.4 GeneDx Sees Growing Demand for Testing
5.5 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
5.6 ClearNote Health Expands Into Immunotherapy Monitoring
5.7 Foundation Medicine to Collaborate on CDx for Lung Cancer
5.8 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
5.9 Lung Cancer Data Heralds Shift for Hummingbird Dx
5.10 PamGene Awarded €7.5M for Immunotherapy Test
5.11 Grail Cancer Test Faces New Clinical Questions
5.12 Freenome Acquires Cancer Dx Firm Oncimmune
5.13 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
5.14 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
5.15 Digital Pathology Meets Cancer Sequencing
5.16 Exact Sciences Preps Expanded Oncology Portfolio
5.17 Qiagen Details Oncology Plans for Digital PCR Platform
5.18 Sema4 Exiting Reproductive Health Screening
5.19 Thermo Fisher Introduces Cancer Profiling Assay
5.20 Genomic Test IDs Cysts Likely to Progress to Cancer
5.21 Naveris to Commercialize Virus-Related Cancer Tests
5.22 Larger Liquid Biopsy Panels Loom
5.23 Halo Diagnostics to Offer Genomic Profiling Tests
5.24 BillionToOne Raises $125M
5.25 Local Cancer Genomic Profiling Options Grow
5.26 German MDx Firm Mainz Biomed Raises $10M in IPO
5.27 Guardant Health Q3 Revenues Up 27 Percent
5.28 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
5.29 Nucleix to Invest in Early-Stage Lung Cancer Dx
5.30 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
5.31 Grail Gets Approval for Galleri Multicancer Test
5.32 Finnish Firms to Form Point-of-Care Testing Firm
5.33 Datar Cancer Genetics Expands to Dx and Screening
5.34 HTG Molecular Diagnostics: HTG Transcriptome Panel
5.35 PacBio's Omniome Acquisition Shortens Path to Clinical
5.36 Invitae to Acquire Genosity for $200M
5.37 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
5.38 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
5.39 Natera Revenues Grow 35 Percent
5.40 AnchorDx Closes $40M Financing Round
5.41 Exact Sciences Strategy for End-to-End Cancer Testing
5.42 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
6 Profiles of Key MDx Companies
6.1 10x Genomics, Inc.
6.2 Abbott Laboratories
6.4 Acuamark Diagnostics
6.5 Adaptive Biotechnologies
6.6 Admera Health, LLC
6.9 Amoy Diagnostics Co., Ltd.
6.12 ARUP Laboratories
6.13 AVIVA Systems Biology
6.14 Baylor Miraca Genetics Laboratories